Fig. 3: Rifaximin use is linked to DAP-R VREfm carriage.
From: Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
Summary of the percentage of VREfm with any rpoB SNP, DAP-associated rpoB SNP (S491F, G482D and H486Y) or DAP-R in patients in the control (n = 116) or rifaximin (n = 96) groups. Data were analysed using one-sided Fisher’s exact tests. Exact P values were as follows: P < 2.2 × 10−16 (any rpoB SNP); P = 3.044 × 10−14 (DAP-associated rpoB SNP) and P = 1.463 × 10−10 (DAP-R).
